VIR_logo_large.jpg
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
October 06, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C....
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
September 30, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
September 27, 2021 07:00 ET | Enochian BioSciences, Inc.
LOS ANGELES, Sept. 27, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 08, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. ...
VIR_logo_large.jpg
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
July 15, 2021 08:30 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
July 12, 2021 07:00 ET | Enochian BioSciences, Inc.
LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Arbutus Biopharma Logo
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
July 07, 2021 07:00 ET | Arbutus Biopharma Corporation
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic...